Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Drug Use Investigation of EYLEA for Central Retinal Vein Occlusion (CRVO)

Next Previous
Trial Profile

Special Drug Use Investigation of EYLEA for Central Retinal Vein Occlusion (CRVO)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Central retinal vein occlusion
  • Focus Adverse reactions
  • Acronyms JPMS-CRVO
  • Sponsors Bayer

Most Recent Events

  • 05 Mar 2019 Status changed from active, no longer recruiting to completed.
  • 17 Mar 2016 Planned End Date changed from 1 Nov 2018 to 1 May 2019 as per ClinicalTrails.gov record.
  • 18 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top